Esophageal squamous cell carcinoma (ESCC) is a common malignant tumor of the digestive system worldwide, especially in China. Due to the lack of effective early detection methods, ESCC patients often present at an advanced stage at the time of diagnosis, which seriously affects the prognosis of patients. At present, early detection of ESCC mainly depends on invasive and expensive endoscopy and histopathological biopsy. Therefore, there is an unmet need for a noninvasive method to detect ESCC in the early stages. With the emergence of a large class of non-invasive diagnostic tools, serum tumor markers have attracted much attention because of their potential for detection of early tumors. Therefore, the identification of serum tumor markers for early detection of ESCC is undoubtedly one of the most effective ways to achieve early diagnosis and treatment of ESCC. This article reviews the recent advances in the discovery of blood-based ESCC biomarkers, and discusses the origins, clinical applications, and technical challenges of clinical validation of various types of biomarkers.
CITATION STYLE
Chu, L. Y., Xie, J. J., Peng, Y. H., Weng, X. F., & Xu, Y. W. (2020, April 21). Blood-based biomarkers for early detection of esophageal squamous cell carcinoma. World Journal of Gastroenterology. Baishideng Publishing Group Co. https://doi.org/10.3748/WJG.V26.I15.1708
Mendeley helps you to discover research relevant for your work.